Pursuant to the provisions of Regulation 30 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Gian Life Care Ltd approved the unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024 on February 14, 2025. Standalone revenue from operations fell sharply to Rs. 158.86 lakhs in Q3 FY25 from Rs. 379.06 lakhs in Q3 FY24, a drop of nearly 58%. For the nine months, revenue declined to Rs. 551.76 lakhs from Rs. 851.68 lakhs, about 35% lower year-on-year. Standalone profit after tax also fell steeply to Rs. 38.37 lakhs in Q3 FY25 versus Rs. 162.64 lakhs a year ago, and to Rs. 63.18 lakhs for nine months versus Rs. 209.58 lakhs previously. Consolidated numbers showed a similar trend with Q3 PAT at Rs. 35.19 lakhs and nine-month PAT at Rs. 56.12 lakhs. The auditor (MSNT & Associates LLP) issued an unmodified review report with no qualifications for both standalone and consolidated results.
Significant year-on-year declines in both revenue (~58% in Q3) and profit (~76% in Q3) indicate weakening business performance and margin pressure for the diagnostics company, which is likely negative for shareholder sentiment and near-term stock price.